Welcome to the PROGEN Blog
Dive into the fascinating world of gene therapy, meet our dedicated PROGEN team, and more.
The Road to Transforming Medicine Through AAVs
Adeno-associated virus (AAV) continues to lead the way in gene therapy research. Discover its evolution since the 1960s and its growing role in transforming treatments for both rare and common diseases.
Producing Reliable Products
Meet Head of Production Rita Lacher and discover how she contributes to transforming ideas into new products.
Top 5 Breakthroughs in LNP Research in 2024
From overcoming blood-brain-barrier to more selective delivery, we've seen some truly exciting advancements in the LNP research field.
CRISPR/Cas Meets AAV: Navigating the Complexities of Gene Editing Delivery
The Challenges and Limitations of In Vivo Delivery of CRISPR/Cas Gene Editing Tools
Science in Action
Meet Head of Research and Development Klaus-Ingmar Pfrepper and find out about his team’s recent discovery of a new AAV antibody.
Overcoming Liver Accumulation: Extrahepatic Targeting Strategies for Lipid Nanoparticles (LNPs)
New targeting strategies are showing how the accumulation of lipid nanoparticles (LNPs) in the liver can be reduced.
Beyond the Virus: How Non-Viral Vectors Are Changing Gene Therapy
Lipid nanoparticles (LNPs), are emerging as promising non-viral vectors, offering distinct advantages that could make them integral to the future of gene therapy.
Five Challenges Of Applying Lipid Nanoparticles As Delivery Tools For Therapeutic Agents
As effective as these delivery vehicles are, they come with their own set of difficulties.
Maximizing Efficiency
Getting a transgene to be expressed inside the target cell is the name of the game.
Bringing New Products to Market
Meet Product Manager Silja Adams, whose work on products is motivated by a desire to help customers meet their needs.
Serving Customers’ Needs
Meet PROGEN’s Business Development Manager Jesse Kay and learn more about why it's important to solve customers' problems.
The Road To Even Safer AAV Gene Therapies
Although AAVs are among the safest gene therapy vectors, they do pose a few risks that can still be reduced.
Comparability Amid Change
When manufacturing changes bring challenges, standard reference materials can save the day.
Helping people become healthy
Meet PROGEN’s co-CEO Maik Lander and learn more about the importance of meeting customers' needs.
Five Reasons to Choose Adeno-associated Viruses for Gene Therapy
These small but mighty DNA delivery vehicles are revolutionizing medicine.
Introducing Recombinant Adeno-associated Viruses (rAAV)
Modifying AAVs makes them more efficient and better at targeting specific tissues.
Supporting the gene therapy community
Meet Katja Betts, co-CEO of PROGEN and find out why supporting the gene therapy community in developing new therapies is her everyday motivation.
